A pharmaceutical patent case being argued next week involves Sanofi-Aventis Deutschland (“Sanofi”) and Mylan Pharmaceuticals Inc. (“Mylan”). This case presents two related issues on the subject of the law of obviousness: (1) whether “obviousness may be shown even when the prior art did not ‘expressly articulate’ or even implicitly ‘suggest’” a modification to the prior art, and (2) whether “the teachings of the challenged patents-in-suit, rather than the prior art,” are sufficient to show that a person of skill in the art (“POSITA”) “would have had a reason to modify the prior art.”
Welcome to Fed Circuit Blog
I’m excited to introduce you to Fed Circuit Blog, a project of the Tsai Center for Law, Science and Innovation at the SMU Dedman School of Law. This blog provides comprehensive coverage of activities and news related to the U.S. Court of Appeals for the Federal Circuit.
In several ways the Federal Circuit is a unique court. Given that it has exclusive jurisdiction over appeals in various types of federal cases, unless the Supreme Court reviews its opinions, these opinions govern nationwide.
The court’s exclusive jurisdiction includes appeals in patent cases. Given the impact of patents on the development and use of technology, the Federal Circuit holds an important place in the innovation ecosystem. As a result, Fed Circuit Blog will provide particular insight into the law governing patent cases and its impact on the innovation ecosystem. That said, Fed Circuit Blog will extend its coverage of the court to other areas of the court’s jurisdiction.
So exactly what information will Fed Circuit Blog provide?